Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Metabolic Disorder Therapeutics Market

Metabolic Disorder Therapeutics Market Share

Report ID: GMI9801
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Metabolic Disorder Therapeutics Market Share

The metabolic disorder therapeutics industry is highly competitive characterized by numerous pharmaceutical companies, biotechnology firms, and healthcare organizations. Established players such as Novo Nordisk, Sanofi, and Eli Lilly dominate the market with their extensive portfolios of diabetes medications, including insulin analogs, oral antidiabetics, and innovative delivery devices. Collaborations between industry leaders and academic institutions drive research and development efforts, fostering innovation and shaping the competitive landscape.

Metabolic Disorder Therapeutics Market Companies

Prominent players operating in the metabolic disorder therapeutics industry include:

AbbVie, Inc.
Actelion Pharmaceuticals Ltd.
Amgen Inc.
AstraZeneca plc
Biocon Ltd.
BioMarin Pharmaceutical, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cipla, Inc.
CymaBay Therapeutics, Inc.
Eli Lilly and Company
Merck KGaA
Novo Nordisk A/S
Sanofi SA
Shire PLC

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

Metabolic disorder therapeutics industry size was USD 74.4 billion in 2023 and will grow at 7.5% CAGR between 2024 and 2032 due to rising prevalence of metabolic disorders, such as diabetes, obesity, and thyroid disorders worldwide.

The hospitals segment in the market will record USD 74.2 billion by 2032, driven by its pivotal role as a primary healthcare provider for patients with complex metabolic conditions.

North America metabolic disorder therapeutics industry will expand at 7.2% CAGR through 2032, attributed to high prevalence rates of conditions like diabetes and obesity, coupled with the sophisticated healthcare infrastructure.

Amgen Inc., AstraZeneca plc, Biocon Ltd., BioMarin Pharmaceutical, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla, Inc., CymaBay Therapeutics, Inc., Eli Lilly and Company, Merck KGaA, Novo Nordisk A/S, and Sanofi SA, among others.